| Literature DB >> 35787812 |
Henriette Farkas1,2, Csilla Máj3, István Kenessey4, Anna Sebestyén5, Ildikó Krencz5, Judit Pápay5, László Cervenak6.
Abstract
BACKGROUND: Hereditary angioedema (HAE) is a rare, life-threatening disease. The knowledge about the molecular pathogenesis of HAE has derived mainly from investigating blood samples. However, limited data are available on the role of the molecular mechanisms in the affected tissues during HAE attack.Entities:
Keywords: Bradykinin receptor; C1-inhibitor deficiency; Hereditary angioedema; Immunohistochemistry; Laryngeal edema; Protease activated receptor 1
Year: 2022 PMID: 35787812 PMCID: PMC9254515 DOI: 10.1186/s13223-022-00699-7
Source DB: PubMed Journal: Allergy Asthma Clin Immunol ISSN: 1710-1484 Impact factor: 3.373
Parameters of primary antibodies used in the study
| Specificity / Dilution | Manufacturer | Catalog number |
|---|---|---|
| BDKRB1 polyclonal antibody, rabbit, 1:50 | Abnova Corporation | PAB26133 |
| BDKRB2 polyclonal antibody, rabbit, 1:50 | Abnova Corporation | PAB26164 |
| PAR1 Rabbit anti-Human Polyclonal (N-Terminus) Antibody, 1:1000 | LifeSpan BioSciences | LS-A2583-50 |
| PAR2 Rabbit anti-Human Polyclonal (N-Terminus) Antibody, 1:100 | LifeSpan BioSciences | LS-A252-50 |
| PAR4 Rabbit anti-Human Polyclonal (C-Terminus) Antibody, 1:100 | LifeSpan BioSciences | LS-A1311-50 |
| Rabbit anti-Human C1-Inhibitor, 1:50 | In-house | – |
| CD3, mmAb, clone: PS-1, 1:50 | BioCare | CM110AK |
| CD19, mmAb, clone: CD19, 1:200 | BioCare | CM310A |
| CD11b (ITAM) rabbit Mab; clone: EPR1344; isotype: Rabbit IgG, ready-to-use | Biogenex | BG-AN546-5 M |
BDKRB1/2 bradykinin B1/B2 receptor; PAR1/2/4 protease activated receptor 1/2/4
Fig. 1Photograph of the HAE patient’s laryngeal sample
Fig. 2Histological comparison of hematoxylin–eosin stained sections from HAE patient and control. A Macrophoto of a median-sagittal opened HAE patient’s sample. B H&E staining of the median-sagittal section. C–F Enlarged images from 4 locations of panel B photo. G–J Corresponding images to (C–F) from the control sample. Scale bar: panel B 5000 μm, panels (C–J) 100 μm
Fig. 3Immunohistochemical staining of C1-Inhibitor and bradykinin receptors. HAE (A) and control (B) epiglottis samples were incubated with affinity purified rabbit anti-human C1-Inhibitor antibody followed by peroxidase conjugated goat anti-rabbit. The immune reaction was developed by DAB and counterstained with hematoxylin. HAE patient’s (C, E) and control’s (D, F) epiglottis samples were incubated with rabbit anti-BDKRB1 antibody (C, D) or anti-BDKRB2 antibody (E, F) followed by a peroxidase conjugated goat anti-rabbit secondary antibody. The immune reaction was developed by DAB and counterstained with hematoxylin. Scale bar: 50 μm
Fig. 4Expression of PAR1 in HAE patient and control. Samples were incubated with rabbit anti-PAR1 antibody followed by peroxidase conjugated goat anti-rabbit secondary antibody. The immune reaction was developed by DAB and counterstained with hematoxylin. HAE patient’s (A, C, E) and control’s (B, D, F) epiglottis (A, B), true vocal cord (C, D) and false vocal cord (E, F) regions are shown. Black arrows indicate endothelial cells and white arrows indicate epithelial cells. Scale bar: 50 μm. Expression pattern of PAR1 in different anatomical locations is compared as staining intensity scores. Green bars represent the control subject’s values, red bars represent the HAE patient’s values. Sum scores (I) were calculated by the summation of epithelial cells (G), endothelial cells (H), leukocytes and interstitial space staining intensity scores (individually ranged from 0 to 3). (EPI: epiglottis, TVC: true vocal cord, FVC: false vocal cord.)